The role of serum HER2 as an alternative to fluorescence in situ hybridization for HER2 in metastatic breast cancer.

被引：0
|
作者：
Kong, SY [1 ]
Kwon, Y [1 ]
Lee, DH [1 ]
Lee, JS [1 ]
Lee, ES [1 ]
Ro, J [1 ]
机构：
[1] Natl Canc Ctr, Goyang, South Korea
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2005年 / 23卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：48S / 48S
页数：1
相关论文
共 50 条
  • [11] SILVER-ENHANCED IN SITU HYBRIDIZATION AS AN ALTERNATIVE TO FLUORESCENCE IN SITU HYBRIDIZATION FOR ASSAYING HER2 AMPLIFICATION IN CLINICAL BREAST CANCER
    Han, S.
    Kim, J. S.
    Gwak, G.
    Park, K.
    ANNALS OF ONCOLOGY, 2012, 23 : 29 - 29
  • [12] Rapid Fluorescence in Situ Hybridization (FISH) for HER2 Assessment in Breast and Gastroesophageal Cancer
    Dokus, B. J.
    Allen, S. F.
    Steinmetz, H. B.
    Marotti, J. D.
    Tsongalis, G. J.
    Tafe, L. J.
    JOURNAL OF MOLECULAR DIAGNOSTICS, 2013, 15 (06): : 908 - 908
  • [13] Evaluation of serum HER2 extracellular domain in in metastatic gastric or gastroesophageal junction cancer: Correlation with HER2 status by immunohistochemistry and fluorescence in situ hybridization and clinicopathologic parameters
    An, Xin
    Dai, Shuqin
    Wang, Fang
    Shao, Qiong
    Chen, Cui
    Chen, Yongchang
    Kong, Yanan
    Li, Cong
    Luo, Huiyan
    Liang, Ying
    Wang, Feng-Hua
    Xu, Rui-hua
    Li, Yu-hong
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [14] Reassessment of HER2 status in HER2 negative or HER2 unknown breast cancer patients with recurrent metastatic disease by analyzing serum HER2 and HER2 status of circulating tumor cells.
    Fehm, T.
    Lane, N.
    Solomayer, E.
    Wallwiener, D.
    Uhr, J.
    BREAST CANCER RESEARCH AND TREATMENT, 2006, 100 : S40 - S40
  • [15] Predicting tissue HER2 status using serum HER2 levels in patients with metastatic breast cancer
    Kong, Sun-Young
    Nam, Byung-Ho
    Lee, Keun Seok
    Kwon, Youngmee
    Lee, Eun Sook
    Seong, Moon-Woo
    Lee, Do Hoon
    Ro, Jungsil
    CLINICAL CHEMISTRY, 2006, 52 (08) : 1510 - 1515
  • [16] Reassessment of HER2 status in breast cancer patients at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, Tania
    TUMOR BIOLOGY, 2007, 28 : 22 - 22
  • [17] Reassessment of HER2 status in breast cancer patients with initially HER2 negative or HER2 unknown primary tumors at the time of metastatic disease by serum HER2 and HER2 status of circulating tumor cells
    Fehm, T.
    Solomayer, E.
    Uhr, J.
    Wallwiener, D.
    ONKOLOGIE, 2008, 31 : 51 - 51
  • [18] Serum HER2 extracellular domain as a potential alternative for tissue HER2 status in metastatic gastric cancer patients
    Peng, Zhi
    Liu, Yi
    Li, Yanyan
    Zhang, Xiaotian
    Zhou, Jun
    Lu, Ming
    Li, Qingqing
    Shen, Lin
    BIOMARKERS IN MEDICINE, 2014, 8 (05) : 663 - 670
  • [19] Correlation of trastuzumab treatment benefit with quantitative HER2 expression levels in HER2 positive metastatic breast cancer.
    Bachmeier, Beatrice
    Sperinde, Jeff
    Weidler, Jodi Marie
    Lie, Yolanda
    Chenna, Ahmed
    Winslow, John
    Engel, Jutta
    Schubert-Fritschle, Gabriele
    Sommerhoff, Christian
    Petropoulos, Christos J.
    Bates, Michael Patrick
    Huang, Weidong
    Nerlich, Andreas
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [20] Serum HER2 in the context of circulating tumor cells in patients with metastatic breast cancer.
    Mueller, Volkmar
    Riethdorf, Sabine
    Rack, Brigitte Kathrin
    Janni, Wolfgang
    Fasching, Peter A.
    Solomayer, Erich
    Aktas, Bahriye
    Kasimir-Bauer, Sabine
    Pantel, Klaus
    Fehm, Tanja N.
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
12345